1
|
Wang C, Wang J, Fang M, Fei B. Genetic evidence causally linking gastroesophageal reflux disease to cholecystitis: a two-sample mendelian randomization study. BMC Gastroenterol 2024; 24:301. [PMID: 39237857 PMCID: PMC11378553 DOI: 10.1186/s12876-024-03390-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Accepted: 08/27/2024] [Indexed: 09/07/2024] Open
Abstract
BACKGROUND Gastroesophageal reflux disease (GERD) and cholecystitis share overlapping symptoms, including belching, acid reflux, and heartburn. Despite this, the causal relationship between these two conditions remains unclear. This study aimed to investigate the causal link between GERD and cholecystitis using a Mendelian randomization (MR) approach. METHODS A two-sample MR analysis was conducted using the inverse variance weighted (IVW), weighted median, weighted mode, and MR-Egger method to assess the causal effects of GERD on the cholecystitis risk. Genome-wide association studies (GWASs) on GERD (N cases = 129080; N controls = 473524) and cholecystitis (N cases = 1930; N controls =359264) were obtained from the IEU Open GWAS project. Various techniques were employed to assess pleiotropy and heterogeneity. RESULTS Seventy-seven single nucleotide polymorphisms from GERD GWASs were selected as instrumental variables (IVs). The primary IVW method revealed a significant association between GERD and an increased risk of cholecystitis (odds ratio = 1.004; 95% confidence interval = 1.003-1.005, p = 2.68 × 10- 9). The absence of heterogeneity and pleiotropy in the data supports the reliability of the results. CONCLUSIONS GERD was positively associated with the risk of cholecystitis. This study provides insights into potential avenues for the development of prevention strategies and treatment options for cholecystitis in patients with GERD. These findings contribute to our understanding of the complex interplay between GERD and cholecystitis.
Collapse
Affiliation(s)
- Chao Wang
- Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan University, Wuxi, 214122, Jiangsu, China
- Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu, China
| | - Jia Wang
- Department of Pain Management, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
- Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu, China
| | - Ming Fang
- Department of Pain Management, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
- Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu, China.
| | - Bojian Fei
- Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan University, Wuxi, 214122, Jiangsu, China.
- Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu, China.
| |
Collapse
|
2
|
Morrison S, Mokoena T. Routine upper gastro-intestinal tract endoscopy before elective cholecystectomy for symptomatic gallstones-justified. Sci Rep 2024; 14:14042. [PMID: 38890422 PMCID: PMC11189552 DOI: 10.1038/s41598-024-64019-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Accepted: 06/04/2024] [Indexed: 06/20/2024] Open
Abstract
Gallstones are common in Western countries and increasing in developing countries through adoption of western lifestyle. Gallstones may cause life-threatening complications, including acute cholecystitis, acute cholangitis, and acute pancreatitis. Cholecystectomy is the treatment of choice for symptomatic gallstones. Presentation of symptomatic gallstones may be indistinguishable from that of other upper gastro-intestinal tract (UGI) pathologies. Some surgeons routinely perform preoperative UGI endoscopy to diagnose and treat concomitant UGI pathology. A prospective cross-sectional observational study was undertaken at University of Pretoria teaching hospitals to evaluate this practice. Patients aged 18 years and older, with symptomatic gallstones but did not satisfy Tokyo guidelines for acute cholecystitis were recruited. UGI endoscopy was performed before cholecystectomy. There were 124 patients, 110 (88.7%) females and 14 (11.3%) males, mean age 44.0 (13.2) (range: 22-78) years. Most common symptoms were right upper quadrant (RUQ) pain (87%), epigastric pain (59.7%), nausea (58.1%) and vomiting (47.9%). Clinically, 80% had RUQ tenderness and 52.4% epigastric tenderness. UGI endoscopy found 35.4% pathology, 28.2% were active, and comprised acute gastritis (27.4%), peptic ulcers (4.8%), duodenitis (3.2%) and oesophagitis (2.4%). Twelve patients had more than one pathology. This warranted treatment before elective cholecystectomy and justifies the practice of routine preoperative UGI endoscopy.
Collapse
Affiliation(s)
- Sherwyn Morrison
- Department of Surgery, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Pretoria, 0001, South Africa
| | - Taole Mokoena
- Department of Surgery, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Pretoria, 0001, South Africa.
| |
Collapse
|
3
|
Majewski M, Sarosiek I, Cooper CJ, Wallner G, McCallum RW, Edlavitch SA, Sarosiek J. Gastric pH and Therapeutic Responses to Exsomeprazole in Patients With Functional Dyspepsia: Potential Clinical Implications. Am J Med Sci 2016; 352:582-592. [PMID: 27916213 DOI: 10.1016/j.amjms.2016.09.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Revised: 08/30/2016] [Accepted: 09/21/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND Therapy for functional dyspepsia remains a challenge. This study aimed to evaluate esomeprazole (E) versus placebo (P) regarding (1) the effectiveness in providing relief of abdominal pain or discomfort during 16 weeks of therapy in patients with functional dyspepsia having moderate or severe symptoms; (2) the effects on gastric acid suppression and (3) the relationship between symptom relief and gastric pH. METHODS Enrolled patients were randomized to E (n = 38) or P (n = 35) in a double-blind, placebo-controlled trial. Outcomes were measured at four 4-week intervals. Drug dose titrated at each visit, based on relief of abdominal symptoms. The 24-hour gastric pH was monitored at baseline, 4 and 8 weeks. RESULTS After 4 weeks, 71% of E patients (40mg) reported satisfactory symptom relief versus 34% of P patients (P < 0.001). When the dose for nonresponders (NR) was titrated to 40mg twice daily, the E relief rate increased to 82% versus 56% in P group (P < 0.05). During the next 4 weeks, with dose decreased by half in responders, E response rate declined to 69% versus 48% in P group (P < 0.10). When the dose was increased for NR during the last 4 weeks, E rate increased to 83% versus 57% in P group (P < 0.05). At 4 and 8 weeks for E responders and NR, patients׳ pH >4 value increased significantly compared to baseline. CONCLUSIONS (1) Though E 40mg once daily is superior to P, some patients benefit from 40mg twice daily; (2) E, 40mg once daily, profoundly inhibits gastric acid secretion; (3) intragastric pH monitoring before and after therapy may help address the relationship between symptomatic relief and gastric acid secretion and (4) some patients respond to monitored titrated placebo therapy.
Collapse
Affiliation(s)
| | - Irene Sarosiek
- Internal Medicine Department, Texas Tech University Health Sciences Center of El Paso, El Paso, Texas
| | - Chad J Cooper
- Internal Medicine Department, Texas Tech University Health Sciences Center of El Paso, El Paso, Texas
| | | | - Richard W McCallum
- Internal Medicine Department, Texas Tech University Health Sciences Center of El Paso, El Paso, Texas
| | - Stanley A Edlavitch
- Department of Psychiatry, University of Missouri School of Medicine, Kansas City, Missouri.
| | - Jerzy Sarosiek
- Internal Medicine Department, Texas Tech University Health Sciences Center of El Paso, El Paso, Texas.
| |
Collapse
|
4
|
Wiklund I, Talley NJ. Update on health-related quality of life in patients with gastroesophageal reflux disease. Expert Rev Pharmacoecon Outcomes Res 2010; 3:341-50. [PMID: 19807381 DOI: 10.1586/14737167.3.3.341] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Gastroesophageal reflux disease is highly prevalent in westernized countries. It damages quality of life but its effect is frequently underestimated, often leading to inadequate management of the disease and its symptoms. Health-related quality of life questionnaires are now becoming more widely recognized as an effective means of demonstrating the true impact of gastroesophageal reflux disease, both on individuals and on society at large. Health-related quality of life questionnaires can also help to underscore the importance of effective acid suppression therapy, with proton pump inhibitors, such as omeprazole and esomeprazole, for this common and highly debilitating condition. This review summarizes recent information on the impact of gastroesophageal reflux disease on a range of aspects of health-related quality of life, including patient well-being.
Collapse
|
5
|
Peura DA, Gudmundson J, Siepman N, Pilmer BL, Freston J. Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci 2007; 52:983-7. [PMID: 17342402 DOI: 10.1007/s10620-006-9156-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2005] [Accepted: 11/16/2005] [Indexed: 12/11/2022]
Abstract
The aim of this study was to evaluate the reasons for trial exclusion among dyspeptic patients and estimate the proportion that may have benefited from proton pump inhibitor (PPI) therapy. Stringent inclusion criteria for enrollment in two multicenter functional dyspepsia trials included dyspepsia (predominant persistent/recurrent upper abdominal discomfort [UAD] during the prior 3 months) of at least moderate intensity during > or =30% of days during the prior 2 to 3 weeks. Exclusion criteria were mild/infrequent UAD; heartburn and UAD of equal frequency; predominant heartburn with UAD; endoscopic evidence of erosive esophagitis or Barrett's or gastric and/or duodenal erosions (>5) or ulcers; irritable bowel syndrome (IBS); other gastrointestinal diagnoses; or other "non-categorized" disorders. Of 2,588 screened patients, 1,667 were excluded. Excluded patients by category had mild/infrequent UAD (12.5%, n=324), heartburn and UAD of equal frequency (1.1%, n=29), predominant heartburn with UAD (11.6%, n=300), endoscopic evidence of erosive esophagitis or Barrett's (6.2%, n=160), gastric and/or duodenal erosions (1.4%, n=36), gastric and/or duodenal ulcers (2.0%, n=53), IBS (7%, n=180), "other" gastrointestinal diagnoses (2.8%, n=73), or other "non-categorized" disorders (19.8%, n=512). Fifty-four percent of patients (902/1,667) had symptoms/diagnoses that would be expected to improve with PPI therapy. Individuals with IBS, "other," or "non-categorized" disorders were considered to have symptoms unlikely to respond to PPI treatment. Empiric PPI treatment would be expected to provide symptom relief to the majority of dyspepsia sufferer who present in clinical practice. PPIs represent the best currently available therapy for acid-related disorders and should be considered the first-line management approach in patients with uninvestigated dyspepsia.
Collapse
Affiliation(s)
- David A Peura
- University of Virginia Health Sciences Center, Charlottesville, VA 22908-0708, USA.
| | | | | | | | | |
Collapse
|
6
|
Mullner K, Molnar B, Tulassay Z. Clinical pharmacological aspects of the proton pump inhibitor therapy – importance of pharmacogenetic differences in the clinical practice. Orv Hetil 2007; 148:543-51. [PMID: 17444020 DOI: 10.1556/oh.2007.27902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
A protonpumpa-gátlók (PPI) a gastrooesophagealis reflux és más savfüggő betegségek kezelésében széles körben használatosak. Az omeprazol, lansoprazol, pantoprazol, rabeprazol és esomeprazol hatékonyan gátolják a gyomorsav-szekréciót a protonpumpa, H
+
/K
+
-adenozin trifoszfatáz (ATPáz) bénításával.E vegyületek döntően CYP-mediált oxidatív metabolizmusában megfigyelhető különbségek kifejezett egyéni eltéréseket okozhatnak a savszekréció gátló hatásban. A PPI-kezelés során fellépő gyógyszerkölcsönhatások nagy része szintén e metabolikus folyamatokhoz köthető.A PPI-k átalakításában elsősorban a CYP2C19 és a CYP3A4 izoenzimek vesznek részt; aktivitásukat részben exogén hatások, részben endogén (farmakogenetikai) tényezők módosíthatják. Napjainkban elérhetővé vált az egyes genotípusok (homozigóta extenzív, heterozigóta extenzív metabolizálók és lassú metabolizálók) PCR, DNS chip módszerrel történő vizsgálata, mely egyre több magyarázattal szolgál a terápiás válaszokban megfigyelhető egyéni eltérések megértéséhez.A genotípus meghatározása a klinikai gyakorlat számára jelentős segítséget nyújthat az optimális kezelési forma kiválasztásában, és egyénre szabott savszekréció-gátló terápia kialakításában, különösen PPI-kezelésre non-responder gastrooesophagealis reflux, vagy fekélybetegség esetében, illetőleg sikertelen eradikációs kezelést követően.
Collapse
Affiliation(s)
- Katalin Mullner
- Semmelweis Egyetem, Altalános Orvostudományi Kar, II Belgyógyászati Klinika, Budapest, Hungary.
| | | | | |
Collapse
|
7
|
Suzuki H, Gotoda T, Sasako M, Saito D. Detection of early gastric cancer: misunderstanding the role of mass screening. Gastric Cancer 2007; 9:315-9. [PMID: 17235635 DOI: 10.1007/s10120-006-0399-y] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2006] [Accepted: 08/30/2006] [Indexed: 02/07/2023]
Abstract
BACKGROUND The proportion of early gastric cancer (EGC) increased from 15% during the 1960s to 50% recently, leading to a remarkable improvement of the 5-year survival rate of gastric cancer patients from 40% to 70%. This has been attributed to mass screening together with extended lymphadenectomy. However, more and more patients with EGC are diagnosed outside of mass screening. The aim of this study was to determine whether patients are symptomatic at the time of early detection and the method of tumor detection. METHODS From 2001 to 2003, a total of 1226 patients (male/female 2.2 : 1.0, age 26-95 years) with EGC were treated at the National Cancer Center Hospital, Tokyo. We reviewed their medical records. RESULTS Of these 1226 patients, 512 (41.8%) were symptomatic, and 714 (58.2%) reported no symptoms. Among the symptomatic patients, 468 (91.4%) were examined at outpatient clinics, 39 (7.6%) by private health assessment clinics, and 5 (1.0%) by mass screening. In total, 91.6% of the symptomatic patients directly underwent esophagogastro-duodenoscopy (EGD). Of the asymptomatic patients, 320 (44.8%) were examined at outpatient clinics, 306 (42.9%) by private health assessment clinics, and 88 (12.3%) by mass screening. EGD was the initial assessment in 67.8% and radiography in 32.2% of asymptomatic patients. CONCLUSION Most patients with EGC were detected outside of mass screening. This suggests that the Japanese public and physicians are well aware of the risk of gastric cancer and the importance of early detection. The effect of mass screening is misunderstood.
Collapse
Affiliation(s)
- Haruhisa Suzuki
- Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
| | | | | | | |
Collapse
|
8
|
Talley NJ, Wiklund I. Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures. Qual Life Res 2005; 14:21-33. [PMID: 15789938 DOI: 10.1007/s11136-004-0613-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Gastroesophageal reflux disease (GERD) is a common, chronic disorder. The main symptom of GERD is heartburn, although a diverse range of symptoms can be associated with the disease including acid regurgitation and epigastric pain. GERD is also a risk factor for Barrett's oesophagus and esophageal adenocarcinoma. The impact of GERD symptoms on patients' lives can be profound and is unrelated to the presence or absence of esophagitis. The impact of GERD can be measured by assessing the patient perspective using Patient Reported Outcomes (PROs). There are two categories of questionnaires that can be used to measure the effect of GERD on health-related quality of life (HRQoL), namely generic and disease or treatment specific. The use of PRO instruments has become more accepted in the assessment of disease treatment. Well-designed instruments that assess physical, psychological and emotional factors can provide clinicians with the data that will promote effective management decisions for the treatment of GERD. The most frequently used instruments in GERD are reviewed here, in terms of their psychometric properties.
Collapse
Affiliation(s)
- Nicholas J Talley
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
| | | |
Collapse
|
9
|
Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2004; 63:2739-54. [PMID: 14664653 DOI: 10.2165/00003495-200363240-00004] [Citation(s) in RCA: 124] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Proton pump inhibitors (PPIs) [omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole] are widely utilised for the treatment of gastro-oesophageal reflux disease, as well as other acid-related disorders. All PPIs suppress gastric acid secretion by blocking the gastric acid pump, H(+)/K(+)-adenosine triphosphatase (ATPase), but the physicochemical properties of these drugs result in variations in the degree of acid suppression, as well as the speed of onset of acid inhibition. Such differences may impact on the clinical performance of PPIs, and this manuscript discusses data that may help clinicians choose between the available PPIs for specific clinical situations and indications. The characteristics of PPIs that have been developed subsequent to omeprazole offer several advantages over this prototype PPI, particularly with respect to the onset of acid suppression and reduced potential for inter-individual pharmacokinetic variation and drug interactions. Newer agents inhibit H(+)/K(+)-ATPase more rapidly than omeprazole and emerging clinical data support potential clinical benefits resulting from this pharmacological property. Although key pharmacokinetic parameters (time to maximum plasma concentration and elimination half-life) do not differ significantly among PPIs, differences in the hepatic metabolism of these drugs can produce inter-patient variability in acid suppression, in the potential for pharmacokinetic drug interactions and, quite possibly, in clinical efficacy. All PPIs undergo significant hepatic metabolism. Because there is no direct toxicity from PPIs, there is minimal risk from the administration of any of them - even to patients with significant renal or hepatic impairment. However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole. Hepatic metabolism is also a key determinant of the potential for a given drug to be involved in clinically significant pharmacokinetic drug interactions. Omeprazole has the highest risk for such interactions among PPIs, and rabeprazole and pantoprazole appear to have the lowest risk.Thus, whereas all PPIs have been shown to be generally effective and safely used for the treatment of acid-mediated disorders, there are chemical, pharmacodynamic and pharmacokinetic differences among these drugs that may make certain ones more, or less, suitable for treating different patient subgroups. Of course, the absolute magnitude of risk from any PPI in terms of drug-drug interactions is probably low - excepting interactions occurring as class effects related to acid suppression (e.g. increased digoxin absorption or inability to absorb ketoconazole).
Collapse
Affiliation(s)
- Malcolm Robinson
- Department of Medicine, Oklahoma Foundation for Digestive Research, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA.
| | | |
Collapse
|
10
|
Affiliation(s)
- C Scarpignato
- Laboratory of Clinical Pharmacology, School of Medicine & Dentistry, University of Parma, Via Volturno 39, 43100 Parma, Italy.
| |
Collapse
|